Cyclin D as a therapeutic target in cancer
The DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer and is a biomarker of cancer phenotype and disease progression. The ability of these cyclins to activate the cyclin-dependent kinases (CDKs) CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target. Is this an effective means of targeting the cyclin D oncogenes, and how might the patient subgroups that are most likely to benefit be identified?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure to modify cyclin D1 on T286 leads to aberrant nuclear accumulation of the protein, premature S phase entry, and enhanced cellular proliferation that drives tumorigenesis (17).”
From A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21 (2023) · cites this paper as [17]
In the citing paper
“Possibly, CCND1 amplification and CDKN2A loss may contribute to determining response to letrozole alone”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [68]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“The deregulation of cyclin expression or CDK activation can directly lead to some of the hallmarks of cance”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 1×
“A second well-described non-catalytic role of cyclin D is the sequestration of p21 and p27 by cyclin D–CDK4/CDK6, leading to the indirect activation of CDK2 (REF”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“It may also be possible to identify low-molecular-mass inhibitors of cyclin–CDK substrate interactions using high-throughput screens that are similar to those used for the discovery and preclinical testing of inhibitors of MDM2–p53 binding (nutlins”
MethodThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“by causing proliferation that is independent of normal extracellular cues, or by over-riding checkpoints that ensure genomic integrity and stabilit”
BackgroundFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387 · cited 1×
“Given the increasingly routine clinical use of specific kinase inhibitor”
BackgroundmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322 · cited 1×
“In Phase II clinical trials mTOR inhibitors were particularly effective in MCL, which is characterized by almost universal overexpression of cyclin D1, although this may not be accompanied by a reduction in cyclin D1 expression (reviewed in REF”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citation
Cited by
Items 101–200 of 1,000
Unraveling the molecular genetics of head and neck cancer through genome-wide approaches
Riaz, N., Morris, L. G. T., Lee, W., & Chan, T. A.-T. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.07.002 · Cited by 121
“CCND1 encodes cyclin D1, which serves as a cofactor for CDK4 and CDK6 to phosphorylate Rb.(72) Again, CDK4/6 inhibitor could serve as a method to target these tumors, and both p16 loss and CCND1 amplification are being investigated as biomarkers in the Palbociclib trial.”
BackgroundXie, S., Zhu, J., Li, J., Zhan, F., Yao, H., Xu, J., & Xu, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00736 · Cited by 117
SAM68: Signal Transduction and RNA Metabolism in Human Cancer
Frisone, P., Pradella, D., Matteo, A. D., Belloni, E., Ghigna, C., & Paronetto, M. P. (2015) · BioMed Research International · doi:10.1155/2015/528954 · Cited by 113
“CCND1 is a protooncogene that is frequently deregulated in several human cancers through different mechanisms, such as chromosomal translocations, amplification of the CCND1 locus, and intragenic mutations [97–99].”
BackgroundAnticancer Properties of Phenolic Acids in Colon Cancer – A Review
Rosa, L. S., & Silva, N. J. A. (2016) · Journal of Nutrition & Food Sciences · doi:10.4172/2155-9600.1000468 · Cited by 108
“Collectively, these observations raise the question of which molecular functions of cyclin D1 are crucial during oncogenesis [23].”
BackgroundMolecular crosstalk between cancer and neurodegenerative diseases
Seo, J., & Park, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03428-3 · Cited by 113
Dörsam, B., Seiwert, N., Foersch, S., Stroh, S., Nagel, G., Begaliew, D., Diehl, E., Kraus, A., McKeague, M., Minneker, V., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712345115 · Cited by 105
“STAT3 has also been implicated in the expression of cyclin D1, which promotes cell proliferation and is overexpressed in human CRC (35).”
Backgroundp120-catenin in cancer – mechanisms, models and opportunities for intervention
Schackmann, R. C. J., Tenhagen, M., van de Ven, R. A. H., & Derksen, P. W. B. (2013) · Journal of Cell Science · doi:10.1242/jcs.134411 · Cited by 100
“Notwithstanding this high variability, several bona fide Kaiso targets (e.g. WNT11, MMP7, CyclinD1) have been strongly linked to cancer (Christiansen et al., 1996; Ii et al., 2006; Musgrove et al., 2011; Uysal-Onganer and Kypta, 2012).”
BackgroundBone morphogenetic protein 4—a fascinating regulator of cancer cell behavior
Kallioniemi, A. H. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.05.009 · Cited by 121
An update on the implications of cyclin D1 in oral carcinogenesis
Ramos‐García, P., Montoya, J. A. G., Scully, C. M., Ayén, Á., González‐Ruiz, L., Navarro‐Triviño, F. J., & González‐Moles, M. Á. (2017) · Oral Diseases · doi:10.1111/odi.12620 · Cited by 113
Differential impact of RB status on E2F1 reprogramming in human cancer
McNair, C. M., Xu, K., Mandigo, A. C., Benelli, M., Leiby, B. E., Rodrigues, D. N., Lindberg, J., Grönberg, H., Crespo, M., Laere, B. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93566 · Cited by 114
Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells
Vergara, D., Simeone, P., Toraldo, D., Boccio, P. D., Vergaro, V., Leporatti, S., Pieragostino, D., Tinelli, A., Domenico, S. D., Alberti, S., et al. (2012) · Molecular BioSystems · doi:10.1039/c2mb05486h · Cited by 104
Gene amplification: mechanisms and involvement in cancer
Matsui, A., Ihara, T., Suda, H., Mikami, H., & Semba, K. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0026 · Cited by 116
“As the well-known role of CCND1 is to induce the G1/S transition together with CDK4/6, CDK inhibitors that compete with ATP for binding to the active site of the kinase have been developed, and some have progressed to clinical trials (83).”
BackgroundDai, M., Al-Odaini, A. A., Fils-Aimé, N., Villatoro, M. A., Guo, J., Arakelian, A., Rabbani, S. A., Ali, S., & Lebrun, J. J. (2013) · Breast Cancer Research · doi:10.1186/bcr3441 · Cited by 100
“Interestingly, some of these cell cycle regulators, in particular cyclin D1 and p21, are often over-expressed in many human cancers and their levels are correlated with high tumor grade, poor prognosis, and increased metastasis in subsets of carcinomas such as breast, prostate, cervical carcinomas and lymphomas [42,43…”
BackgroundA map of protein dynamics during cell-cycle progression and cell-cycle exit
Gookin, S. E., Min, M., Phadke, H., Chung, M., Moser, J. C., Miller, I., Carter, D., & Spencer, S. L. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2003268 · Cited by 113
Whittle, J. R., Vaillant, F., Surgenor, E., Policheni, A. N., Giner, G., Capaldo, B. D., Chen, H.-R., Liu, H. K., Dekkers, J. F., Sachs, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1872 · Cited by 102
“Introduction Estrogen receptor–positive (ERþ) breast cancers frequently exhibit deregulation of the cyclin-dependent kinase 4 and 6 (CDK4/6)/cyclin D1 (CCND1)/retinoblastoma (Rb) signaling pathway, resulting in uncontrolled cellular proliferation (1, 2).”
BackgroundChohan, T. A., Qayyum, A., Rehman, K., Tariq, M., & Akash, M. S. H. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.116 · Cited by 112
Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 109
“CCND2 or CCND3 amplification is rare compared to CCND1 amplification [36, 37].”
BackgroundSun, C., Li, S., & Li, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8482 · Cited by 104
Hosseini‐Zare, M. S., Sarhadi, M., Zarei, M., Thilagavathi, R., & Selvam, C. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113072 · Cited by 106
Parrish, K. E., Pokorny, J. L., Mittapalli, R. K., Bakken, K. K., Sarkaria, J. N., & Elmquist, W. F. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.228213 · Cited by 105
“Lung, breast, and melanoma are the three cancers with the highest propensity to metastasize to the brain and often have mutations in the CDK4/6 pathway (Musgrove et al., 2011; Gállego Pérez-Larraya and Hildebrand, 2014).”
BackgroundCell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers
Hydbring, P., Wang, Y., Fassl, A., Li, X., Matía, V., Otto, T., Choi, Y. J., Sweeney, K. E., Suski, J. M., Yin, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.004 · Cited by 101
“The importance of overexpression of D-type cyclins in pathogenesis of human cancer has been particularly well established (Musgrove et al., 2011).”
Itkonen, H., Engedal, N., Babaie, E., Luhr, M., Guldvik, I., Minner, S., Hohloch, J., Tsourlakis, M., Schlomm, T., & Mills, I. (2014) · Oncogene · doi:10.1038/onc.2014.307 · Cited by 95
miR-18a Inhibits CDC42 and Plays a Tumour Suppressor Role in Colorectal Cancer Cells
Humphreys, K. J., McKinnon, R. A., & Michael, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112288 · Cited by 98
“miR-18a also reduced mRNA levels of CCND1; CCND1 plays an important role in promoting cell cycle progression, and is frequently overexpressed in cancer, including CRC [41].”
BackgroundMolecular targets and anticancer potential of sanguinarine—a benzophenanthridine alkaloid
Galadari, S., Rahman, A. U., Pallichankandy, S., & Thayyullathil, F. (2017) · Phytomedicine · doi:10.1016/j.phymed.2017.08.006 · Cited by 98
Enkner, F., Pichlhöfer, B., Zaharie, A., Krunic, M., Holper, T. M., Janik, S., Moser, B., Schlangen, K., Neudert, B., Walter, K., et al. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0144-8 · Cited by 99
“Inhibitors for these kinases are currently being investigated in clinical trials for various malignancies and might constitute a therapeutic option also for thymic carcinomas [11].”
BackgroundPancholi, S., Ribas, R., Simigdala, N., Schuster, E. F., Nikitorowicz-Buniak, J., Ressa, A., Gao, Q., Leal, M. F., Bhamra, A., Thornhill, A. M., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1284-6 · Cited by 98
Zhang, G., Panigrahy, D., Hwang, S. H., Yang, J., Mahakian, L. M., Wettersten, H. I., Liu, J., Wang, Y., Ingham, E. S., Tam, S. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410432111 · Cited by 97
“Cyclin D1 and cyclin-dependent kinase 4 (CDK4) or cyclin-dependent kinase 6 (CDK6) complex promotes the G1-S transition, whereas p53 family proteins, including p21 and p27, whose transcription is regulated by p53, inhibit the G1-S transition by binding the complexes (24).”
BackgroundJohnson, J. L., Pillai, S., Pernazza, D., Sebti, S. M., Lawrence, N. J., & Chellappan, S. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2647 · Cited by 93
“It iswell established that CDKsphosphorylate and inactivate Rb in the G1 phase of the cell cycle, releasing E2F transcription factors from Rb (8, 28).”
BackgroundChi, H., Tsai, C., Tsai, M.-M., Yeh, C., & Lin, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091903 · Cited by 101
“In view of the finding that Cyclin D1 is an important mediator of the cellular DNA damage response and apoptosis after radiation treatment [90], AK294004 may be a potential lncRNA participating in radioresistance of cancer [89].”
BackgroundAn, H., Kim, J. Y., Oh, E., Lee, N., Cho, Y., & Seo, J. H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141919 · Cited by 95
Cao, L., Zhang, P., Li, J., & Wu, M. (2017) · eLife · doi:10.7554/elife.30433 · Cited by 101
“Mutation, amplification and overexpression of CCND1 are frequently observed in cancer and have been reported to contribute to tumorigenesis (Wiestner et al., 2007; Elsheikh et al., 2008; Musgrove et al., 2011).”
BackgroundLiquid biopsy: one cell at a time
Lim, S. B., Lee, W. D., Vasudevan, J., Lim, W., & Lim, C. T. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0095-0 · Cited by 97
Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation
Wang, J., Su, W., Zhang, T., Zhang, S., Lei, H., Ma, F., Shi, M., Shi, W., Xie, X., & Di, C. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05763-7 · Cited by 101
The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations
Bisteau, X., Caldez, M. J., & Kaldis, P. (2014) · Cancers · doi:10.3390/cancers6010079 · Cited by 99
“D1 overexpression but additional functions of cyclin D1 have been reported (see [131] for a detailed review).”
BackgroundCyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey
Mariaule, G., & Belmont, P. (2014) · Molecules · doi:10.3390/molecules190914366 · Cited by 92
“It is also noteworthy that the deregulation in cancer of cyclins D and their ability to activate CDK4 and CDK6, also makes them an attractive therapeutic target [65].”
BackgroundLi, X., Liu, L. L., Yao, J. L., Wang, K., & Ai, H. (2019) · Stem Cells International · doi:10.1155/2019/8108576 · Cited by 94
Seiler, R., Thalmann, G. N., Rotzer, D., Perren, A. A., & Fleischmann, A. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.125 · Cited by 95
May, F. E. B. (2014) · Cancer Management and Research · doi:10.2147/cmar.s35024 · Cited by 96
Hsp90: Friends, clients and natural foes
Verma, S., Goyal, S., Jamal, S., Singh, A. P., & Grover, A. (2016) · Biochimie · doi:10.1016/j.biochi.2016.05.018 · Cited by 99
Huang, G., Liu, Z., He, L., Luk, K.-H., Cheung, S.-T., Wong, K., & Chen, T. (2018) · Biomaterials Science · doi:10.1039/c8bm00670a · Cited by 91
Li, Y., Wang, J., Zhang, C., Shen, Y., Wang, H., Lei, D., Gu, Y., Lou, J., Zhao, X.-T., Ma, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11040 · Cited by 89
“Of note, overexpression of CCND1 and CCND2 is one of the most common hallmarks of various cancer types, due to its relatively high amplification frequency (15%–40%) and the upregulation of its mRNA and protein expression in a variety of tumors including NSCLC, breast cancer, melanoma, and pancreatic cancer [32].”
BackgroundPalbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Hernandez-Aya, L. F., & Ma, C. X. (2016) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2016.09.017 · Cited by 89
Sammons, S. L., Topping, D. L., & Blackwell, K. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666170330120452 · Cited by 95
“In addition, cyclin D is able to enhance the activity of ER through interactions with ER and its coregulators [22].”
BackgroundSaqub, H., Proetsch-Gugerbauer, H., Bezrookove, V., Nosrati, M., Vaquero, E. M., de Semir, D., Ice, R. J., McAllister, S. D., Soroceanu, L., Kashani–Sabet, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75578-5 · Cited by 95
Li, J., Liu, T., Song, Y., Wang, M., Liu, L., Zhu, H., Li, Q., Lin, J. H., Jiang, H., Chen, K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00257 · Cited by 91
Tao, Z., Blanc, J. M. L., Wang, C., Zhan, T., Zhuang, H., Wang, P., Yuan, Z., & Lü, B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0589 · Cited by 100
“It has, therefore, been shown to be an effective antiproliferative agent against retinoblastoma (Rb)-positive tumor cells in vitro, inducing an exclusiveG1 arrest, with a concomitant reduction of phospho-Ser(780)/Ser(795) on the Rb protein (45, 49, 50).”
BackgroundSix1 Promotes Proliferation of Pancreatic Cancer Cells via Upregulation of Cyclin D1 Expression
Li, Z., Tian, T., Lv, F., Chang, Y., Wang, X., Zhang, L., Li, X., Li, L., Ma, W., Wu, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059203 · Cited by 88
“upregulated in a variety of cancers, including pancreatic cancer, and plays a critical role in tumor initiation and progression [39].”
Background17Beta-Estradiol Signaling and Regulation of Proliferation and Apoptosis of Rat Sertoli Cells1
Royer, C., Lucas, T. F. G., Lazari, M. F. M., & Porto, C. S. (2012) · Biology of Reproduction · doi:10.1095/biolreprod.111.096891 · Cited by 93
New Insights into the Pathogenesis of Alcohol-Induced ER Stress and Liver Diseases
Ji, C. (2014) · International Journal of Hepatology · doi:10.1155/2014/513787 · Cited by 91
“However, a number of studies have shown many new roles of cyclin D [98] and a surprising lack of the correlation of increased cyclin D with proliferation in tumors [99, 100].”
Moulder, D. E., Hatoum, D., Tay, E., Lin, Y., & McGowan, E. M. (2018) · Cancers · doi:10.3390/cancers10060189 · Cited by 83
“Specifically, these include the confirmed roles of p53 in transcriptionally coordinating genes, allied to the nucleotide excision and base excision repair pathways [68,70,71].”
BackgroundInfluentialDivision of labour between Myc and G1 cyclins in cell cycle commitment and pace control
Dong, P., Maddali, M. V., Srimani, J. K., Thélot, F., Nevins, J. R., Mathey-Prevot, B., & You, L. (2014) · Nature Communications · doi:10.1038/ncomms5750 · Cited by 87
Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells
Shimura, T., Noma, N., Oikawa, T., Ochiai, Y., Kakuda, S., Kuwahara, Y., Takai, Y., Takahashi, A., & Fukumoto, M. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.12 · Cited by 86
Targeted therapies for ER+/HER2- metastatic breast cancer
Yamamoto‐Ibusuki, M., Arnedos, M., & André, F. (2015) · BMC Medicine · doi:10.1186/s12916-015-0369-5 · Cited by 95
“cyclin-dependent kinases [20], has resulted in the ap-”
BackgroundInfluentialCurcumin Promotes KLF5 Proteasome Degradation through Downregulating YAP/TAZ in Bladder Cancer Cells
Gao, Y., Shi, Q., Xu, S., Du, C., Liang, L., Wu, K., Wang, K., Wang, X., Chang, L. S.-S., He, D., et al. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150915173 · Cited by 85
“Cyclin D1, a key regulator of cell cycle progression, is frequently amplified and over-expressed in cancers [21].”
BackgroundMechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
Guarducci, C., Bonechi, M., Boccalini, G., Benelli, M., Risi, E., Leo, A. D., Malorni, L., & Migliaccio, I. (2017) · Breast Care · doi:10.1159/000484167 · Cited by 91
Chen, Y., Huang, Y., Gao, X., Li, Y., Lin, J., Chen, L., Chang, L., Chen, G., Guan, Y., Pan, L. K., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01620 · Cited by 100
“The CCND1 gene is considered an oncogene, and it reinforces cell proliferation, growth, angiogenesis, and resistance to chemotherapy and radiotherapy (3, 4).”
BackgroundCDK4: a master regulator of the cell cycle and its role in cancer
Baker, S. J., Poulikakos, P. I., Irie, H. Y., Parekh, S. S., & Reddy, E. P. (2022) · Genes & Cancer · doi:10.18632/genesandcancer.221 · Cited by 90
FAK Is required for c‐Met/β‐catenin‐driven hepatocarcinogenesis
Shang, N., Arteaga, M., Zaidi, A. H., Stauffer, J. K., Cotler, S. J., Zeleznik‐Le, N. J., Zhang, J., & Qiu, W. (2014) · Hepatology · doi:10.1002/hep.27402 · Cited by 91
“Overexpression of cyclin D1 has been related to the development and progression of HCC.(34) Cyclin D1 is increased in MET/CAT-induced tumors and has been shown to mediate MET/CAT-induced hepatocarcinogenesis.”
BackgroundSimpson, N. E., Tryndyak, V. P., Pogribna, M., Beland, F. A., & Pogribny, I. P. (2012) · Epigenetics · doi:10.4161/epi.22713 · Cited by 83
Xu, Y., Huijuan, W., Ma, H., Xu, L., Huo, Y., & Yin, L. (2013) · FEBS Journal · doi:10.1111/febs.12365 · Cited by 94
Aminoacyl-tRNA synthetases and amino acid signaling
Yu, Y. C., Han, J. M., & Kim, S. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118889 · Cited by 89
The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer
Patel, S. A., Hirosue, S., Rodrigues, P., Vojtasova, E., Richardson, E. K., Ge, J., Syafruddin, S. E., Speed, A., Papachristou, E. K., Baker, D., et al. (2022) · Nature · doi:10.1038/s41586-022-04809-8 · Cited by 98
Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer
Sawayama, H., Ogata, Y., Ishimoto, T., Mima, K., Hiyoshi, Y., Iwatsuki, M., Baba, Y., Miyamoto, Y., Yoshida, N., & Baba, H. (2019) · Cancer Science · doi:10.1111/cas.13995 · Cited by 82
Rodriguez, D. A., Ramkairsingh, M., Lin, X., Kapoor, A., Major, P. P., & Tang, D. (2019) · Cancers · doi:10.3390/cancers11071028 · Cited by 85
MiR-29b suppresses the proliferation and migration of osteosarcoma cells by targeting CDK6
Zhu, K., Liu, L., Zhang, J., Wang, Y., Liang, H., Fan, G., Jiang, Z., Zhang, C., Chen, X., & Zhou, G. (2016) · Protein & Cell · doi:10.1007/s13238-016-0277-2 · Cited by 83
“This article is published with open access at Springerlink.com and journal.hep.com.cn P ro te in & C e ll cycle-inhibitory ‘brake’ that governs cell cycle transitions during quiescence, senescence and differentiation (Musgrove et al., 2011).”
BackgroundInfluentialConnecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response
Corkery, D., Holly, A. C., Lahsaee, S., & Dellaire, G. (2015) · Nucleus · doi:10.1080/19491034.2015.1062194 · Cited by 96
“This includes the splicing of cyclin D1 (CCND1), a proto-oncogene frequently deregulated in human cancers.(124,125) Alternative splicing of the CCND1 gene produces a variant transcript (CyclinD1b) which retains intron 4.”
BackgroundSchwaederle, M. C., Elkin, S. K., Tomson, B. N., Carter, J. L., & Kurzrock, R. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1053669 · Cited by 86
The contribution of alternative polyadenylation to the cancer phenotype
Masamha, C. P., & Wagner, E. J. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx096 · Cited by 85
“This allows activation of the E2F transcription factors and allows for the expression of genes that are required for DNA synthesis and G1 to S-phase transition (34,35).”
Fu, H., Gao, H., Qi, X., Zhao, L., Wu, D., Bai, Y., Li, H., Liu, X., Hu, J. X., & Shao, S. (2018) · 癌症:英文版 · doi:10.1186/s40880-018-0290-3 · Cited by 83
PES1 promotes breast cancer by differentially regulating ERα and ERβ
Cheng, L., Li, J., Han, Y.-J., Lin, J., Niu, C., Zhou, Z., Yuan, B., Huang, K., Li, J., Jiang, K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62676 · Cited by 90
“Overexpression of cyclin D1, the major regulatory subunit for CDK4, is common in human cancers of epithelial cell origin (49).”
Hussain, A., Sharma, C., Khan, S., Shah, K., & Haque, S. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.7.2939 · Cited by 80
Sublethal effects of zinc oxide nanoparticles on male reproductive cells
Liu, Q., Xu, C. Y., Ji, G., Liu, H., Mo, Y., Tollerud, D. J., Gu, A., & Zhang, Q. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.05.017 · Cited by 80
Runx2 Is a Novel Regulator of Mammary Epithelial Cell Fate in Development and Breast Cancer
Owens, T. W., Rogers, R. L., Best, S. A., Ledger, A., Mooney, A.-M., Ferguson, A., Shore, P., Swarbrick, A., Ormandy, C. J., Simpson, P. T., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0053 · Cited by 75
“(34) Cyclin D1 is an established oncogene in a number of tissues, however correlation of cyclin D1 expression with patient prognosis provides varying results (41-43).”
Yao, S., Cheng, M. M., Zhang, Q., Wasik, M. A., Kelsh, R. N., & Winkler, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063757 · Cited by 83
Cyclin D1 Activity Regulates Autophagy and Senescence in the Mammary Epithelium
Brown, N. E., Jeselsohn, R., Bihani, T., Hu, M. G., Foltopoulou, P., Kuperwasser, C., & Hinds, P. W. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4139 · Cited by 72
“growth-promoting signals (including those dependent on ErbB2) can increase the levels or activity of cyclin D1 (14, 42) and, at the same time, inhibit autophagy (5, 43), we reasoned that autophagy might be upregulated in cyclin D1 mammary tissues to compensate for reduced cyclin D1 activity.”
Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer
Shan, Y., Hsu, H., Lai, M., Hung, Y., Wang, C., Yen, M., & Chen, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6736 · Cited by 84
“There have been three isoforms, cyclin D1 (CCND1); cyclin D2 (CCND2); and cyclin D3 (CCND3), identified in humans (9,10).”
BackgroundUbiquitin ligases in cancer: Functions and clinical potentials
Duan, S., & Pagano, M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.008 · Cited by 85
Role of autophagy in head and neck cancer and therapeutic resistance
Sannigrahi, M. K., Singh, V., Sharma, R., Panda, N., & Khullar, M. (2014) · Oral Diseases · doi:10.1111/odi.12254 · Cited by 78
miR-603 promotes glioma cell growth via Wnt/β-catenin pathway by inhibiting WIF1 and CTNNBIP1
Guo, M., Zhang, X., Wang, G., Sun, J., Jiang, Z., Khadarian, K. A., Yu, S., Zhao, Y., Xie, C., Zhang, K. X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.003 · Cited by 77
Saito, K., & Cui, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041091 · Cited by 78
“The estrogen signaling through ERα regulates the expression of various genes that play key roles in cell proliferation and cell-cycle progression [48,49].”
BackgroundHsu, T., Wang, M.-C., Chen, S.-Y., Huang, S., Yeh, Y., Su, W., Chang, W., & Hung, J. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.078485 · Cited by 76
Reddy, M. V. R., Akula, B., Cosenza, S. C., Divakar, S. K. A., Mallireddigari, M. R., Pallela, V. R., Billa, V. K., Subbaiah, D. R. C. V., Bharathi, E. V., Carpio, R. V., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401073p · Cited by 80
Salinomycin induces cell death via inactivation of Stat3 and downregulation of Skp2
Koo, K. H., Kim, H., Bae, Y.-K., Kim, K., Park, B.-K., Lee, C.-H., & Kim, Y.-N. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.223 · Cited by 81
“Cyclin D1 is overexpressed in several cancers and is a biomarker of cancer phenotype and disease progression, indicating that targeting of cyclin D1 oncogenes appears to be an attractive therapeutic strategy.(25) As negative regulators of the G1/S-phase transition, p21Cip1/p27Kip1 and the INK4 proteins are inhibitors…”
BackgroundLi, M., Tian, L., Wang, L., Yao, H., Zhang, J., Lu, J., Sun, Y., Gao, X., Xiao, H., & Liu, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077829 · Cited by 74
“Cyclin D1 is an important promoter of the G1-S transition during the cell cycle [36].”
BackgroundMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents
Inamdar, A. A., Goy, A. H., Ayoub, N. M., Attia, C., Oton, L., Taruvai, V., Costales, M., Lin, Y., Pecora, A. L., & Suh, K. S. (2016) · Oncotarget · doi:10.18632/oncotarget.8961 · Cited by 79
Wang, H., Ge, X., Qu, H., Wang, N., Zhou, J., Xu, W., Xie, J., Zhou, Y., Shi, L., Qin, Z., et al. (2020) · Cancer Management and Research · doi:10.2147/cmar.s244481 · Cited by 78
Kopechek, J. A., Carson, A. R., McTiernan, C. F., Chen, X., Hasjim, B. J., Lavery, L., Sen, M., Grandis, J. R., & Villanueva, F. S. (2015) · Theranostics · doi:10.7150/thno.12822 · Cited by 80
“STAT3 downstream genes Bcl-xL and cyclin D1 promote cancer cell survival and proliferation through inhibition of apoptosis and cell cycle progression, respectively, and are frequently overexpressed in human squamous cell carcinomas [36-38].”
BackgroundmiR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3
Zhang, Y., Huang, W. M., Ran, Y., Xiong, Y., Zhong, Z., Fan, X., Wang, Z., & Ye, Q. (2015) · Tumor Biology · doi:10.1007/s13277-015-3582-0 · Cited by 76
Chen, S.-H., Gong, X., Zhang, Y., Horn, R. D. V., Yin, T., Huber, L., Burke, T., Manro, J. R., Iversen, P. W., Wu, W., et al. (2017) · Oncogene · doi:10.1038/onc.2017.384 · Cited by 77
Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
Li, Z., Zou, W., Zhang, J., Zhang, Y., Xu, Q., Li, S., & Chen, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580251 · Cited by 81
miR-577 inhibits glioblastoma tumor growth via the Wnt signaling pathway
Zhang, W., Shen, C., Li, C., Yang, G., Liu, H., Chen, X., Zhu, D., Zou, H., Zhen, Y., Zhang, D., et al. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22304 · Cited by 74
“Overexpression of cyclin D1 has been reported in many different cancer types and believed to be a promising target for therapy [41].”
BackgroundXia, W. G., Lo, C. M., Poon, R. Y. C., Cheung, T. T., Chan, A. C. Y., Chen, L., Yang, S., Tsao, G. S., & Wang, X. Q. (2017) · Oncotarget · doi:10.18632/oncotarget.16402 · Cited by 75
“Cyclin D1 is also a well-established human oncogene and is important for the development and progression of several cancers [7].”
BackgroundStrategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia
Follini, E., Marchesini, M., & Roti, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123021 · Cited by 79
“Amplification of cyclin D genes and overexpression of their related proteins is a common feature of several human cancers [144].”
BackgroundJing, W., Guo, X., Wang, G., Bi, Y., Han, L., Zhu, Q., Qiu, C., Tanaka, M., & Zhao, Y. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106012 · Cited by 74
Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer
Hu, W., Fan, C., Jiang, P., Ma, Z., Yan, X., Di, S., Jiang, S., Li, T. X., Cheng, Y., & Yang, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6228 · Cited by 73
“The overexpression of cyclin D1 alters cell cycle progression, which may contribute to tumorigenesis; indeed, cyclin D1 overexpression has been observed in various cancers [91].”
BackgroundLiquid biopsies to occult brain metastasis
Rehman, A. U., Κhan, P., Maurya, S. K., Siddiqui, J. A., Santamaria‐Barria, J. A., Batra, S. K., & Nasser, M. W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01577-x · Cited by 78
“Likewise, cyclin D1 overexpressed in BC and melanoma could be involved in TME modulation for the survival of metastatic cells in the brain microenvironment [207, 208].”
BackgroundBaba, Y., Watanabe, M., Murata, A., Shigaki, H., Miyake, K., Ishimoto, T., Iwatsuki, M., Iwagami, S., Yoshida, N., Oki, E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1645 · Cited by 76
“Together with its binding partner cyclin D1, CDK6 forms active complexes that promote cellular proliferation by phosphorylating and inactivating the retinoblastoma protein (40).”
Zang, Y., Li, J., Wan, B., & Tai, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14925 · Cited by 74
Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells
Pae, J., Ersching, J., Castro, T. B. R., Schips, M., Mesin, L., Allon, S. J., Ordovás-Montañés, J., Mlynarczyk, C., Melnick, A. M., Efeyan, A., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201699 · Cited by 78
“A major regulator of E2F activity are the D-type cyclins, which in partnership with cyclin dependent kinases (CDKs) 4 and 6, activate E2F by phosphorylation of its negative regulator RB (Musgrove et al., 2011).”
BackgroundPalbociclib-induced autophagy and senescence in gastric cancer cells
Valenzuela, C. A., Vargas, L., Martinez, V., Bravo, S., & Brown, N. E. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.031 · Cited by 67
Metadata
- Authors
- Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, Robert L.
- ORCID
- Caldon, C. Elizabeth
- Venue
- Nature Reviews Cancer
- Published
- 2011-07-07
- Volume
- 11
- Issue
- 8
- Pages
- 558-572
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2089655089
- Cited by
- 1,370
- References
- 190
- Citations by year
- 2026: 54 · 2025: 65 · 2024: 57 · 2023: 78 · 2022: 85 · 2021: 102 · 2020: 113 · 2019: 100 · 2018: 93 · 2017: 130 · 2016: 129 · 2015: 105 · 2014: 92 · 2013: 91 · 2012: 75
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- cyclin D1, cyclin D, cyclin-dependent kinases, CDK4, CDK6, oncogene deregulation, cancer therapy, therapeutic target, biomarkers, patient subgroup identification, tumor progression
- MeSH terms
- Humans, Neoplasms, Oncogenes, Polymorphism, Genetic, Cyclin D
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.